Safety and immunogenicity of a prefusion non-stabilized spike protein mRNA COVID-19 vaccine: a phase I trial.
Gatechompol S, Kittanamongkolchai W, Ketloy C, Prompetchara E, Thitithanyanont A, Jongkaewwattana A, Buranapraditkun S, Alameh MG, Ubolyam S, Sophonphan J, Apornpong T, Kerr S, Kamarulzaman A, Siwamogsatham S, Kroon E, Puthanakit T, Patarakul K, Palaga T, Wijagkanalan W, Carpenter A, Hong L, Weissman D, Ruxrungtham K; ChulaVAC-001 study team.
Gatechompol S, et al. Among authors: palaga t.
Nat Microbiol. 2022 Dec;7(12):1987-1995. doi: 10.1038/s41564-022-01271-0. Epub 2022 Nov 14.
Nat Microbiol. 2022.
PMID: 36376393
Clinical Trial.